{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:04:44Z","timestamp":1762956284674,"version":"3.37.3"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"DOI":"10.1093\/rheumatology\/keaa090","type":"journal-article","created":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T12:09:40Z","timestamp":1581163780000},"page":"1797-1798","source":"Crossref","is-referenced-by-count":5,"title":["Tofacitinib in cardiovascular outcomes: friend or foe?"],"prefix":"10.1093","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3881-0266","authenticated-orcid":false,"given":"Wenhui","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"key":"2020072516474869000_keaa090-B1"},{"key":"2020072516474869000_keaa090-B2"},{"key":"2020072516474869000_keaa090-B3","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/acr.23930","article-title":"Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis across phase III and long-term extension studies","volume":"71","author":"Gladman","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2020072516474869000_keaa090-B4","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1080\/21691401.2019.1573740","article-title":"Tofacitinib inhibits ox-LDL-induced adhesion of THP-1 monocytes to endothelial cells","volume":"47","author":"Yang","year":"2019","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"2020072516474869000_keaa090-B5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.bbrc.2017.06.020","article-title":"Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice","volume":"490","author":"Wang","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"2020072516474869000_keaa090-B6","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X19895492","article-title":"Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Xie","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2020072516474869000_keaa090-B7"},{"key":"2020072516474869000_keaa090-B8","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00296-017-3844-9","article-title":"Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study","volume":"37","author":"Kume","year":"2017","journal-title":"Rheumatol Int"},{"key":"2020072516474869000_keaa090-B9","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/art.40798","article-title":"Comparative risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors: a cohort study of rheumatoid arthritis patients","volume":"71","author":"Desai","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2020072516474869000_keaa090-B10","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/apt.15514","article-title":"Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme","volume":"50","author":"Sandborn","year":"2019","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/8\/1797\/33532389\/keaa090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/8\/1797\/33532389\/keaa090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T20:49:40Z","timestamp":1595710180000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/8\/1797\/5804119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":10,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,3,12]]},"published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa090","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"type":"print","value":"1462-0324"},{"type":"electronic","value":"1462-0332"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,3,12]]}}}